Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he's ready for his...
Myeloma NZ
Dr. Munshi on latest treatment developments in multiple myeloma
US FDA approves first non-gene edited allogeneic CAR T-cell candidate for trials
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more:...
Lenalidomide-based maintenance therapy may be the most effective in myeloma
Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma...
University hospitals seidman cancer center launches new CAR-T therapy trial
University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a...
Pediatric CAR T-cell therapy guidelines highlight need for interdisciplinary monitoring
Children treated with chimeric antigen receptor T-cell therapy experience unique toxicities that require careful monitoring to prevent serious...
Selecting a proteasome inhibitor in multiple myeloma
Panelists: A. Keith Stewart, MB, ChB, Mayo Clinic; Sagar Lonial, MD, FACP, Emory University School of Medicine; Thomas Martin, MD, UCSF Helen Diller...
Pre-cancer bone health may help to predict myeloma outcomes
When it comes to multiple myeloma, patients’ bone health can have major implications on their outcomes – even before they are diagnosed, according...
Myeloma could be caught early using simple blood tests
A collaborative project in the UK between researchers from the University of Oxford, the University of Exeter and Chiddenbrook Surgery, Crediton,...
North Wales cancer patient first in the world to trial new myeloma treatment
A North Wales cancer patient has become the first in the world to take part in a new trial looking for a more effective treatment for myeloma. The...
NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients
A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology...
Bortezomib-Based Therapy Effective for Relapsed/Refractory Myeloma
A group of “real-world” patients with relapsed or refractory multiple myeloma had high response rates and an overall survival (OS) of about 3 years...